Experienced in Ureteral Reconstruction

Dr. Mark E. Borowsky

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Hackensack Meridian Health Medical Group - Specialty Care PC
1945 Route 33, 
Neptune, NJ 
Experienced in Ureteral Reconstruction
Hackensack Meridian Health Medical Group - Specialty Care PC
1945 Route 33, 
Neptune, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Borowsky is a Gynecologic Oncologist and an Oncologist in Neptune, New Jersey. Dr. Borowsky is rated as an Experienced provider by MediFind in Ureteral Reconstruction. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Ureteral Reconstruction, and Hernia Surgery.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in DE
Hospital Affiliations
Ocean Medical Center
Riverview Medical Center
Jfk University Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1945 Route 33, Neptune, NJ 07753
Other Locations
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
3600 Route 66, Fl 3, Neptune, NJ 07753
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
425 Jack Martin Blvd, Fl 2, Brick, NJ 08724
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
30 Prospect Ave, Suite 2, Hackensack, NJ 07601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Enrollment Status: Completed
Publish Date: August 25, 2023
Intervention Type: Biological, Drug, Device
Study Drugs: VGX-3100, Imiquimod Cream
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 6 Less Clinical Trials

17 Total Publications

Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Journal: Southern medical journal
Published: October 03, 2023
Similar Doctors
Advanced in Ureteral Reconstruction
Dr. Yukio Sonoda
Gynecologic Oncology | Oncology
Advanced in Ureteral Reconstruction
Dr. Yukio Sonoda
Gynecologic Oncology | Oncology

Msk Harrison

500 Westchester Ave, 
West Harrison, NY 
 (59.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yukio Sonoda is a Gynecologic Oncologist and an Oncologist in West Harrison, New York. Dr. Sonoda is rated as an Elite provider by MediFind in Ureteral Reconstruction. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy.

Experienced in Ureteral Reconstruction
Dr. James R. Bosscher
Gynecologic Oncology | Oncology
Experienced in Ureteral Reconstruction
Dr. James R. Bosscher
Gynecologic Oncology | Oncology
19 Davis Ave Fl 1, 
Neptune, NJ 
 (0.1 miles away)
732-897-7944
Languages Spoken:
English

James Bosscher is a Gynecologic Oncologist and an Oncologist in Neptune, New Jersey. Dr. Bosscher is rated as an Advanced provider by MediFind in Ureteral Reconstruction. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Ureteral Reconstruction.

Experienced in Ureteral Reconstruction
Dr. Randolph B. Deger
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in Ureteral Reconstruction
Dr. Randolph B. Deger
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Virtua Medical Group, PA

200 Bowman Dr, Suite E325, 
Voorhees, NJ 
 (53.3 miles away)
856-247-7420
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Randolph Deger is a Gynecologic Oncologist and an Oncologist in Voorhees, New Jersey. Dr. Deger is rated as a Distinguished provider by MediFind in Ureteral Reconstruction. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteral Reconstruction, and Hysterectomy. Dr. Deger is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borowsky's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile